Literature DB >> 15678151

Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses.

Hongxun Sang1, Vladimir M Pisarev, Jennifer Chavez, Simon Robinson, Yajun Guo, Lori Hatcher, Corey Munger, Cathy B Talmadge, Joyce C Solheim, Rakesh K Singh, James E Talmadge.   

Abstract

Transfection of tumors with tumor-associated antigens (Ags) or cytokines can increase immunogenicity and slow down tumor growth. However, the effect of cotransfection with genes that encode a tumor-associated Ag, such as the tumor suppressor gene p53, and a cytokine has been rarely investigated. We report that transfection of 4T1 mammary tumor cells (p53-null) with the dendritic cell (DC) growth factor, fms-like tyrosine kinase 3 ligand (Flt3L), significantly delayed their growth in vivo, resulting in the rejection of 100% of the tumors formed by injection of tumor cells cotransfected with Flt3L and p53. Immunization with irradiated 4T1 cells transfected with Flt3L induced DC infiltration of the immunization site and significantly increased the antitumor T-cell responses. Further, immunization with irradiated 4T1 cells cotransfected with p53 and Flt3L significantly increased p53-specific immune responses, as compared to vaccination with 4T1 cells transfected with either Flt3L or p53 alone. These responses included increased activity against clone 66 (Cl-66), a sister tumor to 4T1 with high murine mutant p53 expression levels. Challenge with Cl-66 revealed that immunization with irradiated 4T1-Flt3L-p53 cells significantly slowed growth, prolonged survival, and resulted in complete remissions. Further, immunization with irradiated 4T1-Flt3L also slowed Cl-66 growth, although to a lesser extent than 4T1-Flt3L-p53. We suggest that immunization with DCs transfected with the Flt3L transgene and a tumor Ag may potentially heighten T-cell responses and therapeutic activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15678151     DOI: 10.1038/sj.cgt.7700809

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  6 in total

1.  DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis.

Authors:  Matjaz Humar; Martina Maurer; Marc Azemar; Bernd Groner
Journal:  J Cancer Res Clin Oncol       Date:  2008-10-10       Impact factor: 4.553

Review 2.  Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression.

Authors:  Jing Jin; Yi Li; Qijie Zhao; Yue Chen; Shaozhi Fu; JingBo Wu
Journal:  Cell Commun Signal       Date:  2021-05-06       Impact factor: 5.712

3.  An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.

Authors:  Amar Jyoti; Kyle D Fugit; Pallavi Sethi; Ronald C McGarry; Bradley D Anderson; Meenakshi Upreti
Journal:  Sci Rep       Date:  2015-10-15       Impact factor: 4.379

4.  The bovine dialysable leukocyte extract IMMUNEPOTENT CRP induces immunogenic cell death in breast cancer cells leading to long-term antitumour memory.

Authors:  Alejandra Reyes-Ruiz; Kenny Misael Calvillo-Rodriguez; Ana Carolina Martínez-Torres; Cristina Rodríguez-Padilla
Journal:  Br J Cancer       Date:  2021-02-03       Impact factor: 7.640

5.  The role of surface chemistry-induced cell characteristics on nonviral gene delivery to mouse fibroblasts.

Authors:  Tadas Kasputis; Angela K Pannier
Journal:  J Biol Eng       Date:  2012-09-11       Impact factor: 4.355

6.  3D tumor tissue analogs and their orthotopic implants for understanding tumor-targeting of microenvironment-responsive nanosized chemotherapy and radiation.

Authors:  Pallavi Sethi; Amar Jyoti; Elden P Swindell; Ryan Chan; Ulrich W Langner; Jonathan M Feddock; Radhakrishnan Nagarajan; Thomas V O'Halloran; Meenakshi Upreti
Journal:  Nanomedicine       Date:  2015-08-15       Impact factor: 5.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.